Acute exacerbation of rheumatoid arthritis-associated interstitial lung disease triggered by COVID-19: What is the best practice for treatment?

Toshiyuki Yonezawa; Atsushi Suzuki; Kensuke Fukumitsu; Takuma Katano; Hisashi Kako; Makoto Ishii; Akio Niimi; Kazuyoshi Imaizumi; Koji Sakamoto; Norihito Omote; Etsuro Yamaguchi

doi:10.1016/j.rmcr.2023.101857

Acute exacerbation of rheumatoid arthritis-associated interstitial lung disease triggered by COVID-19: What is the best practice for treatment?

Toshiyuki Yonezawa
, Atsushi Suzuki
, Kensuke Fukumitsu
, Takuma Katano
, Hisashi Kako
, Makoto Ishii
, Akio Niimi
, Kazuyoshi Imaizumi
, Koji Sakamoto
, Norihito Omote
, Etsuro Yamaguchi

Research output: Contribution to journal › Article › peer-review

Abstract

We present a case of 79-year-old female with rheumatoid arthritis-associated interstitial lung disease (RA-ILD) developed an acute exacerbation (AE) triggered by coronavirus disease 2019 (COVID-19). The patient was unresponsive to a combination therapy of remdesivir, dexamethasone, and tocilizumab. Given that a recent multicenter cohort study reported ILD as a poor prognostic contributor in patients with RA and COVID-19, there may be potentially a certain number of patients with AE of RA-ILD triggered by COVID-19. This case highlights the need for a discussion how to treat these patients in a daily clinical practice.

Original language	English
Article number	101857
Journal	Respiratory Medicine Case Reports
Volume	43
DOIs	https://doi.org/10.1016/j.rmcr.2023.101857
Publication status	Published - 01-2023
Externally published	Yes

All Science Journal Classification (ASJC) codes

Pulmonary and Respiratory Medicine

Access to Document

10.1016/j.rmcr.2023.101857

Cite this

Yonezawa, T., Suzuki, A., Fukumitsu, K., Katano, T., Kako, H., Ishii, M., Niimi, A., Imaizumi, K., Sakamoto, K., Omote, N., & Yamaguchi, E. (2023). Acute exacerbation of rheumatoid arthritis-associated interstitial lung disease triggered by COVID-19: What is the best practice for treatment? Respiratory Medicine Case Reports, 43, Article 101857. https://doi.org/10.1016/j.rmcr.2023.101857

@article{71e12a5ec95e43559f958db78c9216bf,

title = "Acute exacerbation of rheumatoid arthritis-associated interstitial lung disease triggered by COVID-19: What is the best practice for treatment?",

abstract = "We present a case of 79-year-old female with rheumatoid arthritis-associated interstitial lung disease (RA-ILD) developed an acute exacerbation (AE) triggered by coronavirus disease 2019 (COVID-19). The patient was unresponsive to a combination therapy of remdesivir, dexamethasone, and tocilizumab. Given that a recent multicenter cohort study reported ILD as a poor prognostic contributor in patients with RA and COVID-19, there may be potentially a certain number of patients with AE of RA-ILD triggered by COVID-19. This case highlights the need for a discussion how to treat these patients in a daily clinical practice.",

keywords = "Acute exacerbation, COVID-19, Interstitial lung diseases, Rheumatoid arthritis, Treatment",

author = "Toshiyuki Yonezawa and Atsushi Suzuki and Kensuke Fukumitsu and Takuma Katano and Hisashi Kako and Makoto Ishii and Akio Niimi and Kazuyoshi Imaizumi and Koji Sakamoto and Norihito Omote and Etsuro Yamaguchi",

note = "Publisher Copyright: {\textcopyright} 2023 The Authors",

year = "2023",

month = jan,

doi = "10.1016/j.rmcr.2023.101857",

language = "English",

volume = "43",

journal = "Respiratory Medicine Case Reports",

issn = "2213-0071",

publisher = "W.B. Saunders Ltd",

}

Yonezawa, T, Suzuki, A, Fukumitsu, K, Katano, T, Kako, H, Ishii, M, Niimi, A, Imaizumi, K, Sakamoto, K, Omote, N & Yamaguchi, E 2023, 'Acute exacerbation of rheumatoid arthritis-associated interstitial lung disease triggered by COVID-19: What is the best practice for treatment?', Respiratory Medicine Case Reports, vol. 43, 101857. https://doi.org/10.1016/j.rmcr.2023.101857

TY - JOUR

T1 - Acute exacerbation of rheumatoid arthritis-associated interstitial lung disease triggered by COVID-19

T2 - What is the best practice for treatment?

AU - Yonezawa, Toshiyuki

AU - Suzuki, Atsushi

AU - Fukumitsu, Kensuke

AU - Katano, Takuma

AU - Kako, Hisashi

AU - Ishii, Makoto

AU - Niimi, Akio

AU - Imaizumi, Kazuyoshi

AU - Sakamoto, Koji

AU - Omote, Norihito

AU - Yamaguchi, Etsuro

PY - 2023/1

Y1 - 2023/1

N2 - We present a case of 79-year-old female with rheumatoid arthritis-associated interstitial lung disease (RA-ILD) developed an acute exacerbation (AE) triggered by coronavirus disease 2019 (COVID-19). The patient was unresponsive to a combination therapy of remdesivir, dexamethasone, and tocilizumab. Given that a recent multicenter cohort study reported ILD as a poor prognostic contributor in patients with RA and COVID-19, there may be potentially a certain number of patients with AE of RA-ILD triggered by COVID-19. This case highlights the need for a discussion how to treat these patients in a daily clinical practice.

AB - We present a case of 79-year-old female with rheumatoid arthritis-associated interstitial lung disease (RA-ILD) developed an acute exacerbation (AE) triggered by coronavirus disease 2019 (COVID-19). The patient was unresponsive to a combination therapy of remdesivir, dexamethasone, and tocilizumab. Given that a recent multicenter cohort study reported ILD as a poor prognostic contributor in patients with RA and COVID-19, there may be potentially a certain number of patients with AE of RA-ILD triggered by COVID-19. This case highlights the need for a discussion how to treat these patients in a daily clinical practice.

KW - Acute exacerbation

KW - COVID-19

KW - Interstitial lung diseases

KW - Rheumatoid arthritis

KW - Treatment

UR - https://www.scopus.com/pages/publications/85153485535

UR - https://www.scopus.com/pages/publications/85153485535#tab=citedBy

U2 - 10.1016/j.rmcr.2023.101857

DO - 10.1016/j.rmcr.2023.101857

M3 - Article

AN - SCOPUS:85153485535

SN - 2213-0071

VL - 43

JO - Respiratory Medicine Case Reports

JF - Respiratory Medicine Case Reports

M1 - 101857

ER -

Acute exacerbation of rheumatoid arthritis-associated interstitial lung disease triggered by COVID-19: What is the best practice for treatment?

Abstract

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this